Stocks and Investing Stocks and Investing
Wed, November 9, 2011

Europe Situation Forecasts Change - Report Highlights Ford Motor Company and Human Genome Sciences


Published on 2011-11-09 06:09:36 - Market Wire
  Print publication without navigation


November 09, 2011 09:00 ET

Europe Situation Forecasts Change - Report Highlights Ford Motor Company and Human Genome Sciences

NEW YORK, NY--(Marketwire - Nov 9, 2011) - Today, [ www.BrightonMarkets.com ] announced new reports highlighting Ford Motor Company (NYSE: [ F ]) and Human Genome Sciences (NASDAQ: [ HGSI ]). Gain market insight with full analysis and research downloads available at [ www.BrightonMarkets.com/index.php?coa=F&cob=HGSI ].

With the European Financial Stability Facility set to increase to $1.4 trillion, it marks a significant move forward to strengthen the safety net in place for Europe's most troubled countries. Private bondholders of Greek debt are settling at a 50% haircut as another $180 billion in fresh aid is set to arrive, enabling banks to recapitalize at a healthy 9% reserve. Overall, these measures will bring Greece's debt burden down to 120% of GDP by 2020. An important consideration is political commitment to this road map. Currently the global community appears to be on point with ECB's initiative, an outlook that should be sufficient to support markets around current levels.

Brighton Markets is releasing new coverage on Ford Motor Company for its current position within the consumer goods industry. Ford Motor Company (Ford) is a producer of cars and trucks. Ford and its subsidiaries are also engaged in other businesses, including financing vehicles. It operates under two segments: Automotive and Financial Services. Automotive segment includes the operations of Ford North America, Ford South America, Ford Europe and Ford Asia Pacific Africa. The full research report on Ford Motor Company (NYSE: [ F ]) is available here: [ www.BrightonMarkets.com/index.php?coa=F ].

Brighton Markets has released research on Human Genome Sciences for its changing role within the healthcare industry. Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company's products are BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. GlaxoSmithKline (GSK) is a HGS partner in the co-development and commercialization of BENLYSTA. The full research report on Human Genome Sciences (NASDAQ: [ HGSI ]) is available here: [ www.BrightonMarkets.com/index.php?cob=HGSI ].

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.


Contributing Sources